References
- Stupp R, Mason WP, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
- Chakravarti A, Palanichamy K. Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res 2008;139:173–89.
- Mohapatra G, Bollen AW, Kim DH, et al. Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer 1998;21:195–206.
- Webber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 1996;13:983–94.
- Mir T, Dirks P, Mason WP, Bernstein M. Are patients open to elective resampling of their glioblastoma? A new way of assessing treatment innovations. Acta Neurochir 2014;156:1855–63.
- Strauss AL, Corbin JM. Basics of qualitative research: grounded theory procedures and techniques. Beverly Hills, CA: Sage Publications Inc.; 1990.
- Knifed E, Lipsman N, Mason W, Bernstein M. Patients’ perception of the informed consent process for neurooncology trials. Neuro Oncol 2008;10:348–54.
- Bernstein M. Neuro-oncology: under-recognized mental incapacity in brain tumor patients. Nat Rev Neurol 2014;10:487–8.
- Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005;102:5814–19.
- Quick J, Gessler F, Dützmann S, et al. Benefit of tumor resection for recurrent glioblastoma. J Neurooncol 2014;117:365–72.
- Robinson NJ, Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol 2014;119:7–15.
- Friedmann-Morvinishi D. Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog 2014;19:327–36.